{"nctId":"NCT01406223","briefTitle":"Mechanistic Evaluations of Pre-Cessation Therapies for Smoking Cessation","startDateStruct":{"date":"2011-07"},"conditions":["Nicotine Dependence"],"count":282,"armGroups":[{"label":"varenicline","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Varenicline","Drug: Nicotine patches","Other: Placebo bupropion","Other: Placebo patch"]},{"label":"NRT (nicotine patches only)","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Nicotine patches","Other: Placebo varenicline","Other: Placebo bupropion"]},{"label":"varenicline + bupropion","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Varenicline","Drug: Bupropion","Drug: Nicotine patches","Other: Placebo patch"]},{"label":"Post-quit NRT","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Nicotine patches","Other: Placebo varenicline","Other: Placebo bupropion","Other: Placebo patch"]}],"interventions":[{"name":"Varenicline","otherNames":["Chantix"]},{"name":"Bupropion","otherNames":["Zyban"]},{"name":"Nicotine patches","otherNames":["Nicoderm"]},{"name":"Placebo varenicline","otherNames":[]},{"name":"Placebo bupropion","otherNames":[]},{"name":"Placebo patch","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Are generally healthy;\n* Are 18-50 years old;\n* Smoke an average of at least 10 cigarettes per day for at least three cumulative years;\n* Have an afternoon expired air carbon monoxide (CO) reading of at least 10ppm;\n* Are right-handed as measured by a two-item scale used in our laboratory;\n* Express a desire to quit smoking in the next thirty days.\n* Potential subjects must agree to use acceptable contraception during their participation in this study.\n\nPotential subjects must agree to avoid the following during their participation in this study:\n\n* participation in any other nicotine-related modification strategy outside of this protocol;\n* use of tobacco products other than cigarettes, including pipe tobacco, cigars, e-cigarettes, snuff, and chewing tobacco;\n* use of experimental (investigational) drugs or devices;\n* use of illegal drugs;\n* use of opiate medications.\n\nExclusion Criteria:\n\n* Inability to attend all required experimental sessions;\n* Presence of conditions that would make MRI unsafe (e.g. pacemaker);\n* Hypertension (systolic \\>140 mm Hg, diastolic \\>100 mm Hg, coupled with a history of hypertension); subjects with no previous diagnosis of hypertension may have a screening blood pressure up to 160/100.\n* Hypotension with symptoms (systolic \\<90 mm Hg, diastolic \\<60 mm Hg).\n* Coronary heart disease;\n* Lifetime history of heart attack;\n* Cardiac rhythm disorder (irregular heart rhythm);\n* Chest pains (unless history, exam, and ECG clearly indicate a non-cardiac source);\n* Cardiac (heart) disorder (including but not limited to valvular heart disease, heart murmur, heart failure);\n* History of skin allergy;\n* Active skin disorder (e.g., psoriasis) within the last five years, except minor skin conditions (including but not limited to facial acne, minor localized infections, and superficial minor wounds);\n* Liver or kidney disorder (except kidney stones, gallstones);\n* Gastrointestinal problems or disease other than gastroesophageal reflux or heartburn;\n* Active ulcers in the past 30 days;\n* Lung disorder (including but not limited to Chronic obstructive pulmonary disease (COPD), emphysema, and asthma);\n* Brain abnormality (including but not limited to stroke, brain tumor, and seizure disorder);\n* Migraine headaches that occur more frequently than once per week;\n* Recent, unexplained fainting spells;\n* Problems giving blood samples;\n* Diabetes;\n* Current cancer or treatment for cancer in the past six months (except basal or squamous cell skin cancer);\n* Other major medical condition;\n* Current psychiatric disease (with the exception of anxiety disorders, Obsessive-compulsive disorder (OCD) and Attention deficit hyperactivity disorder (ADHD));\n* Bulimia or anorexia;\n* Suicidal ideation (within the past 10 years) or lifetime occurrence of attempted suicide;\n* Current depression;\n* Pregnant or nursing mothers;\n* Alcohol abuse;\n* Significant adverse reaction to nicotine patch, bupropion/Wellbutrin/Zyban or Chantix/Varenicline in the past.\n* Use (within the past 30 days) of:\n\n  * Illegal drugs (or if the urine drug screen is positive);\n  * Experimental (investigational) drugs;\n  * Psychiatric medications including antidepressants, anti-psychotics or any other medications that are known to affect smoking cessation (e.g. clonidine);\n  * Smokeless tobacco (chewing tobacco, snuff), cigars or pipes;\n  * Nicotine replacement therapy or any other smoking cessation aid.\n* Use (within the past 14 days) of:\n\n  * Opiate medications for pain or sleep (non-opiate medication for pain or sleep will be allowed).","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"50 Years","stdAges":["ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"The Amygdala, Anterior Insula, and Medial Prefrontal Cortex Scans Will be Compared to Evaluate Significant Differences","description":"Mean blood-oxygen-level dependent (BOLD) contrast sensitive functional magnetic resonance imaging (fMRI) cue-reactivity signal following 2 week pre-quit treatment, controlling for baseline cue-reactivity.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.057","spread":"0.285"},{"groupId":"OG001","value":".007","spread":".186"},{"groupId":"OG002","value":".160","spread":".258"},{"groupId":"OG003","value":".129","spread":".278"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":".051","spread":".337"},{"groupId":"OG001","value":"-.014","spread":".190"},{"groupId":"OG002","value":".134","spread":".266"},{"groupId":"OG003","value":".020","spread":".249"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":".094","spread":".196"},{"groupId":"OG001","value":".013","spread":".244"},{"groupId":"OG002","value":"-.015","spread":".160"},{"groupId":"OG003","value":".179","spread":".288"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-.008","spread":".224"},{"groupId":"OG001","value":".065","spread":".305"},{"groupId":"OG002","value":".019","spread":".188"},{"groupId":"OG003","value":".082","spread":".333"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":".129","spread":".162"},{"groupId":"OG001","value":".026","spread":".294"},{"groupId":"OG002","value":"-.120","spread":".562"},{"groupId":"OG003","value":".009","spread":".200"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":".058","spread":".171"},{"groupId":"OG001","value":"-.010","spread":".277"},{"groupId":"OG002","value":"-.176","spread":".641"},{"groupId":"OG003","value":"-.017","spread":".178"}]}]}]},{"type":"SECONDARY","title":"Days to First Cigarette Following Quitting Smoking","description":"Days to first cigarette (i.e. lapse) will be measured via self-report.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.15","spread":"22.143"},{"groupId":"OG001","value":"15.21","spread":"26.066"},{"groupId":"OG002","value":"9.90","spread":"23.960"},{"groupId":"OG003","value":"5.73","spread":"18.666"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":18},"commonTop":["Vivid Dreams","Coughing","Headache","Dry Mouth","Thirst"]}}}